Dennis Podlesak - 29 Oct 2026 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
30 Oct 2026, 19:09:48 UTC
Prior SEC filing
06 Feb 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Michael A. Metzger, Attorney-in-Fact
Filing notes and source

Key filing fact

Dennis Podlesak filed Form 4 for Syndax Pharmaceuticals Inc (SNDX) on 30 Oct 2026.

Key facts

  • This page summarizes Dennis Podlesak's Form 4 filing for Syndax Pharmaceuticals Inc (SNDX).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 30 Oct 2026, 19:09.

Change

  • Previous filing in this sequence was filed on 06 Feb 2026.
  • Current net transaction value: -$113,716.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001314595 Primary reporting owner

Podlesak Dennis

Relationship
Director
Address
C/O SYNDAX PHARMACEUTICALS, INC., 730 THIRD AVENUE, FLOOR 9, NEW YORK
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Signature date
30 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SNDX transaction

Common Stock

Options Exercise

Transaction value
Shares
+8,000
Change %
+3.3%
Price
$11.81*
Shares after
247,763
Date
29 Oct 2026
Ownership
Direct
SNDX transaction

Common Stock

Sale

Transaction value
-$113,716
Shares
-8,000
Change %
-3.2%
Price
$14.21
Shares after
239,763
Date
29 Oct 2026
Ownership
Direct
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SNDX transaction Derivative

Stock Options (Right to buy)

Options Exercise

Transaction value
Shares
-8,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
29 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
8,000
Exercise price
$11.81
Footnotes
F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to Octobre 31, 2026. Following the sales reported in this Form 4, the Reporting Person has a total of 127,000 options to purchase shares of common stock that are vested and immediately exercisable and no unvested options to purchase shares of common stock.

Footnote F2

The sale prices ranged from $14.00 to $14.59.

Footnote F3

This option is fully vested.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .